Insider · CIK 0001586660
George Golumbeski
Files at ABOS (Acumen Pharmaceuticals, Inc.), SAGE (Sage Therapeutics, Inc.), STTK (Shattuck Labs, Inc.), MURA (Mural Oncology plc). First filing -, latest -.
George Golumbeski files SEC Form 4 as director at ABOS (Acumen Pharmaceuticals, Inc.), and also at SAGE (Sage Therapeutics, Inc.), STTK (Shattuck Labs, Inc.), MURA (Mural Oncology plc). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; George Golumbeski has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Common Stock | +35,500 | $0.00 | $0 | 35,500 | Jun 5, 2026 |
| Jun 3, 2026 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +53,250 | $0.00 | $0 | 53,250 | Jun 5, 2026 |
| May 29, 2026 | STTK Shattuck Labs, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +81,000 | $0.00 | $0 | 81,000 | Jun 2, 2026 |
| Dec 5, 2025 | MURA Mural Oncology plc | DDisposition to issuer Stock Option (right to buy)derivative | -8,637 | - | - | 0 | Dec 5, 2025 |
| Dec 5, 2025 | MURA Mural Oncology plc | DDisposition to issuer Stock Option (right to buy)derivative | -15,334 | - | - | 0 | Dec 5, 2025 |
| Nov 6, 2025 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Nov 10, 2025 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | UTender of shares Common Stock | -8,000 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,593 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -21,500 | - | - | 0 | Jul 31, 2025 |
| Jul 14, 2025 | STTK Shattuck Labs, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +33,150 | $0.00 | $0 | 33,150 | Jul 16, 2025 |
| Jun 11, 2025 | MURA Mural Oncology plc | AGrant or award Stock Option (right to buy)derivative | +8,637 | $0.00 | $0 | 8,637 | Jun 13, 2025 |
| Jun 11, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +21,500 | $0.00 | $0 | 21,500 | Jun 13, 2025 |
| Jan 3, 2025 | SAGE Sage Therapeutics, Inc. | AGrant or award Stock Options (Right to buy)derivative | +13,593 | $0.00 | $0 | 13,593 | Jan 6, 2025 |
Questions about George Golumbeski
Answered from the filings on this page, as of the latest one.
Is George Golumbeski buying or selling?
George Golumbeski has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did George Golumbeski's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and George Golumbeski has 0.
Where does George Golumbeski file Form 4?
George Golumbeski has filed Form 4 at ABOS (Acumen Pharmaceuticals, Inc.); SAGE (Sage Therapeutics, Inc.); STTK (Shattuck Labs, Inc.); MURA (Mural Oncology plc). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.